Non Small Cell Lung Cancer (Stage III)Phase 3LAURANCT03521154
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
A Phase 3 study testing Osimertinib 80mg/40mg in people with Non Small Cell Lung Cancer (Stage III), run by AstraZeneca at 118 sites in 17 countries.
Trial summary
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer Read more about this study
- Who is it for?
- Ages 18 to 130 years
- Conditions the study is for
- Non Small Cell Lung Cancer (Stage III)
- What is being tested?
- Osimertinib 80mg/40mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 216 participants
- Where
- 118 sitesin 17 countries
- Study dates
- 19 Jul 2018to 29 Oct 2027
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 130 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female aged at least 18 years.
- Patients with histologically documented NSCLC of predominantly non-squamous Pathology who present with locally advanced, unresectable (Stage III) disease (according to Version 8 of the International Association for the Study of Lung Cancer [IASLC] Staging Manual in Thoracic Oncology).
- The tumor harbours one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations, assessed by cobas® EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne® test in a CLIA certified (USA sites) or an accredited local laboratory (sites outside of the USA) or by central testing (cobas® v2 only).
- Patients must have received either concurrent chemoradiation or sequential chemoradiation including at least 2 cycles of platinum based chemotherapy and a total dose of radiation of 60 Gy ±10% (54 to 66 Gy).
- Chemoradiation must be completed ≤6 weeks prior to randomization.
- Patients must not have had disease progression during or following definitive platinum-based, chemoradiation therapy.
Show all 9Show fewer
- World Health Organization (WHO) performance status of 0 or 1.
- Life expectancy >12 weeks at Day 1.
- Female patients who are not abstinent (in line with the preferred and usual lifestyle choice) must be using adequate contraceptive measures, must not be breast feeding, and must have a negative pregnancy test prior to first dose of study drug; or female patients must have an evidence of non-childbearing potential.
Who cannot join
- Mixed small cell and non-small cell lung cancer histology
- History of interstitial lung disease (ILD) prior to chemoradiation
- Symptomatic pneumonitis following chemoradiation
- Any unresolved toxicity Common Terminology Criteria for Adverse Events (CTCAE) > Grade 2 from the prior chemoradiation therapy
- Any of the following cardiac criteria:
- Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs
Show all 17Show fewer
- Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG
- Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes
- Inadequate bone marrow reserve or organ function
- History of other malignancies, except: adequately treated non-melanoma skin cancer or lentigo maligna , curatively treated in-situ cancer, or other solid tumors curatively treated with no evidence of disease for > 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.
- Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib
- Prior treatment with any prior chemotherapy, radiation therapy, immunotherapy or investigational agents for NSCLC outside of that received in the definitive setting for Stage III disease (chemotherapy and radiotherapy in SCRT and CCRT regimens is allowed for treatment of Stage III disease).
- Prior treatment with EGFR-TKI therapy
- Major surgery as defined by the investigator within 4 weeks of the first dose of study drug.
- Patients currently receiving (unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 weeks prior to receiving the first dose of study drug).
- Contraindication to MRI, including but not limited to, claustrophobia, pace makers, metal implants, intracranial surgical clips and metal foreign bodies
Trial locations and contacts
118 sites in 17 countries.
118 sites in 17 countries
China16 sites
Research Site
Beijing, 100021
Research Site
Beijing, 100730
Research Site
Changchun, 130000
Research Site
Changsha, 410013
Research Site
Chengdu, 610041
Research Site
Guangzhou, 510100
Research Site
Hangzhou, 310003
Research Site
Hangzhou, 310006
Research Site
Hangzhou, 310022
Research Site
Jinan, 250117
Research Site
Linhai, 317000
Research Site
Shanghai, 200030
Research Site
Shanghai, 200032
Research Site
Ürümqi, 830099
Research Site
Wuhan, 430022
Research Site
Wuhan, 430030
Japan13 sites
Research Site
Hiroshima, 734-8551
Research Site
Kanazawa, 920-8641
Research Site
Kashiwa, 227-8577
Research Site
Nagoya, 460-0001
Research Site
Niigata, 951-8566
Research Site
Osaka, 541-8567
Research Site
Sakaishi, 591-8555
Research Site
Sapporo, 003-0804
Research Site
Sayama, 589-8511
Research Site
Sendai, 981-0914
Research Site
Shinjuku-ku, 160-0023
Research Site
Sunto-gun, 411-8777
Research Site
Yokohama, 241-8515
Brazil9 sites
Research Site
Barretos, 14784-400
Research Site
Curitiba, 81520-060
Research Site
Florianópolis, 88034-000
Research Site
Fortaleza, 60336-045
Research Site
Porto Alegre, 90160-093
Research Site
Porto Alegre, 90610-000
Research Site
Ribeirão Preto, 14021-636
Research Site
São Paulo, 01221-0100
Research Site
São Paulo, 01246-000
India9 sites
Research Site
Bangalore, 560068
Research Site
Gūrgaon, 122001
Research Site
Hubli, 580025
Research Site
Karamsad, 388325
Research Site
Kolkata, 700160
Research Site
Nashik, 422002
Research Site
New Delhi, 110063
Research Site
New Delhi, 110085
Research Site
New Delhi, 11029
Russia8 sites
Research Site
Kazan', 420029
Research Site
Kostroma, 156005
Research Site
Moscow, 121205
Research Site
Novisibirsk, 630082
Research Site
Obninsk, 249036
Research Site
Saint Petersburg, 197022
Research Site
Saint Petersburg, 197758
Research Site
Ufa, 450054
Taiwan8 sites
Research Site
Kaohsiung City, 83301
Research Site
Taichung, 402
Research Site
Taichung, 40447
Research Site
Taichung, 40705
Research Site
Tainan, 70403
Research Site
Taipei, 10002
Research Site
Taipei, 11217
Research Site
Taoyuan, 00333
Thailand8 sites
Research Site
Bangkok, 10300
Research Site
Bangkok, 10330
Research Site
Bangkok, 10400
Research Site
Bangkok, 10700
Research Site
Hat Yai, 90110
Research Site
Khon Kaen, 40002
Research Site
Lampang, 52000
Research Site
Mueang, 50200
Turkey (Türkiye)8 sites
Research Site
Adana, 01120
Research Site
Adapazarı, 54290
Research Site
Ankara, 06280
Research Site
Ankara, 6200
Research Site
Ankara
Research Site
Istanbul, 34030
Research Site
Istanbul, 34854
Research Site
Izmir, 35620
Spain7 sites
Research Site
Barcelona, 08003
Research Site
Madrid, 28040
Research Site
Madrid, 28046
Research Site
Málaga, 29010
Research Site
San Sebastián, 20014
Research Site
Seville, 41009
Research Site
Valencia, 46009
United States5 sites
Research Site
Atlanta, Georgia, 30322
Research Site
Duarte, California, 91010
Research Site
Florham Park, New Jersey, 07932
Research Site
Madison, Wisconsin, 53792
Research Site
Salt Lake City, Utah, 84106
Argentina5 sites
Research Site
Ciudad Autónoma de Bs. As., 1426
Research Site
Ciudad Autónoma de Bs. As., C1199ABB
Research Site
Mar del Plata, 7600
Research Site
Rosario, 2000
Research Site
San Salvador de Jujuy, 4600
Peru5 sites
Research Site
Lima, LIMA 31
Research Site
Lima, Lima 32
Research Site
Lima, LIMA 34
Research Site
Lima, LIMA 41
Research Site
San Isidro, 27
South Korea5 sites
Research Site
Cheongju-si, 28644
Research Site
Incheon, 21565
Research Site
Seongnam-si, 13620
Research Site
Seoul, 05505
Research Site
Seoul, 06351
Hungary4 sites
Research Site
Budapest, 1083
Research Site
Budapest, 1121
Research Site
Gyöngyös - Mátraháza, 3200
Research Site
Pécs, 7623
Vietnam4 sites
Research Site
Hà Nội, 100000
Research Site
Hanoi, 100000
Research Site
Ho Chi Minh City, 700000
Research Site
Ho Chi Minh City, 70000
Malaysia3 sites
Research Site
George Town, 10450
Research Site
Kuala Lumpur, 59100
Research Site
Kuala Selangor, 46050
About this study
Official title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA).
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
Read the detailed description
This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable EGFR mutation-positive NSCLC, including the most common EGFR sensitising mutations (Ex19Del and L858R), either alone or in combination with other EGFR mutations. Chemoradiation may have been given either given concurrently or sequentially. Patients whose disease has not progressed following chemoradiation will be randomised within 6 weeks of completion of chemoradiation to receive osimertinib or placebo in a 2:1 ratio, and treatment will be continued until disease progression, unacceptable toxicity or other discontinuation criteria are met. After progression, patients can be unblinded and may receive open-label osimertinib. After the final OS analysis, the study blind will be broken and patients still receiving open-label osimertinib will be supplied with open-label osimertinib by AstraZeneca for as long as their treating physician considers they are deriving clinical benefit.
- Conditions
- Non Small Cell Lung Cancer (Stage III)
- Being tested
- Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg
- Keywords
- Phase III, Osimertinib, Non Small Cell Lung Cancer (Stage III), Unresectable NSCLC, EGFR, chemoradiation therapy
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Osimertinib 80mg/40mgDrug
The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
Placebo Osimertinib 80mg/40mgDrug
The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily.
Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met
| Study group | Role | What they receive |
|---|---|---|
| Osimertinib | Experimental | Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule. Receives: Drug: Osimertinib 80mg/40mg |
| Placebo Osimertinib | Placebo comparator | Matching placebo for Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule Receives: Drug: Placebo Osimertinib 80mg/40mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)
Time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on BICR assessment according to RECIST v1.1
Measured: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Secondary outcomes (15)
Number of Participants With Progression-free Survival (PFS) Events in Patients With EGFR Ex19del or L858R Mutation
Number of PFS events (PFS is time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on BICR assessment according to RECIST v1.1)
Measured: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Number of Participants With Progression-free Survival (PFS) Events in Patients With EGFR Mutations Ex19del or L858R Detectable in Plasma-derived ctDNA
Number of PFS events (PFS is time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on blinded independent central review (BICR) assessment according to RECIST v1.1)
Measured: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Central Nervous System (CNS) Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)
Time from randomisation until the date of CNS disease progression or death (by any cause in the absence of CNS progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on CNS BICR assessment according to RECIST v1.1
Measured: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Overall Survival (Count)
Number of patients with Overall Survival (OS), the time from the date of randomisation until date of death by any cause
Measured: Date of randomisation to date of death by any cause. Assessed up to a maximum of approximately 63 months
Overall Survival (Duration)
Time from the date of randomisation until death by any cause
Measured: Date of randomisation to date of death by any cause. Assessed up to a maximum of approximately 63 months
Objective Response Rate by Blinded Independent Central Review (BICR)
Percentage of evaluable patients with at least one BICR assessed visit response of complete response (CR) or partial response (PR). CR defined as disappearance of all target lesions (TL) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to <10mm. PR defined as >= 30% decrease in the sum of diameters of target lesions (compared to baseline sum of diameters). Responses include both confirmed and unconfirmed BICR responses
Measured: Every 8 weeks for first 48 weeks, then every 12 weeks until radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Duration of Response, Unconfirmed by Blinded Independent Central Review (BICR)
Date of PFS event - date of first unconfirmed response + 1 day (and expressed in months) for unconfirmed responses only
Measured: Every 8 weeks for first 48 weeks, then every 12 weeks until radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Disease Control Rate by Blinded Independent Central Review (BICR)
Percentage of patients who have a best overall response of complete response (CR), partial response (PR) or stable disease (SD) as assessed by BICR
Measured: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Tumour Shrinkage by Blinded Independent Central Review (BICR)
Depth of response (or tumour shrinkage or change in tumour size) was assessed using BICR responses in target lesions. The best change in tumour size is the largest decrease from baseline or the smallest increase from baseline in the absence of a reduction
Measured: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Proportion With Tumour Shrinkage by Blinded Independent Central Review (BICR)
Proportion with depth of response (or tumour shrinkage or change in tumour size)
Measured: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Time to Death or Distant Metastases by Blinded Independent Central Review (BICR)
Time from the date of randomisation until the first date of distant metastases or date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is detected on a scan that is anywhere other than lung or regional lymph node according to RECIST v1.1 or proven by biopsy
Measured: Time from randomisation to the date of distant metastases or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Time to Study Treatment Discontinuation
Time from randomisation to the earlier of the date of study treatment discontinuation (regardless of the reason for study treatment discontinuation) or death (i.e. date of study treatment discontinuation/death or censoring - date of randomisation + 1 day, expressed in months)
Measured: Time from randomisation to the earlier of the date of study treatment discontinuation or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Time to First Subsequent Treatment
Time from the date of randomisation to the earlier of the date of anti-cancer therapy start date following study drug discontinuation or death
Measured: Time from randomisation to the start of first subsequent anti-cancer therapy or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Time to Second Subsequent Treatment
Time from the date of randomisation to the earlier of the second subsequent anti-cancer therapy start date following study drug discontinuation or death
Measured: Time from randomisation to the start of second subsequent anti-cancer therapy or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Second Progression-free Survival (PFS2)
Time from randomisation to the earliest progression event following first objective disease progression, subsequent to the first subsequent therapy, or death.
Measured: Every 8 weeks for first 48 weeks, then every 12 weeks. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2018
- Study start19 Jul 2018
- Primary completion5 Jan 2024
- Study completion29 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Non Small Cell Lung Cancer (Stage III)Studies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 216 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Suresh S Ramalingam, MD, Principal investigator, Emory University School of Medicine, Atlanta, U.S.Shun Lu, MD, Principal investigator, Shanghai Chest Hospital, Shanghai, China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03521154
- Sponsor's protocol ID
- D5160C00048
- Other IDs
- 2022-500860-36-00, 2018-001061-16, 2018
- Acronym
- LAURA
- Status last verified
- Jul 2026
- First submitted
- 20 Apr 2018
- Last updated
- 4 Aug 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Publications
Kato T, Dong X, Takahashi T, Soparattanapaisarn N, Geater SL, Wang CL, Arriola E, Moiseenko F, Thompson L, Grainger E, Armenteros-Monterroso E, Evans A, Bolanos A, Ramalingam SS, Lu S. Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study. Lung Cancer. 2026 Aug;218:109486. doi: 10.1016/j.lungcan.2026.109486. Epub 2026 Jun 6.
PubMed 42296617Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Ozguroglu M, Casarini I, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS. A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery. Future Oncol. 2026 May;22(11):1247-1262. doi: 10.1080/14796694.2026.2652543. Epub 2026 Apr 27.
PubMed 42037107Arriola E, Casarini I, Ozguroglu M, Huang M, Takahashi T, Lai X, Goto K, Maneenil K, Lee KH, Cobo M, Valdiviezo N, Evans A, Bolanos A, Huang X, Lai R, Ramalingam SS. Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy. Eur J Cancer. 2026 Jun 3;240:116744. doi: 10.1016/j.ejca.2026.116744. Epub 2026 Apr 12.
PubMed 42019226Murat-Onana ML, Ramalingam SS, Janne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X. EGFR mutation testing across the osimertinib clinical program. Lung Cancer. 2025 Jun;204:108549. doi: 10.1016/j.lungcan.2025.108549. Epub 2025 Apr 18.
PubMed 40311309Lu S, Ahn MJ, Reungwetwattana T, Ozguroglu M, Kato T, Yang JC, Huang M, Fujiki F, Inoue T, Quang LV, Sriuranpong V, Vicente D, Fuentes C, Chaudhry AA, Poole L, Armenteros Monterroso E, Rukazenkov Y, van der Gronde T, Ramalingam SS. Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study. Ann Oncol. 2024 Dec;35(12):1116-1125. doi: 10.1016/j.annonc.2024.08.2243. Epub 2024 Sep 16.
PubMed 39289145Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Ozguroglu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS; LAURA Trial Investigators. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2.
PubMed 38828946Tu CY, Hsia TC, Lin YC, Liang JA, Li CC, Chien CR. Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors. Can Respir J. 2024 Mar 5;2024:8889536. doi: 10.1155/2024/8889536. eCollection 2024.
PubMed 38476120Lu S, Casarini I, Kato T, Cobo M, Ozguroglu M, Hodge R, van der Gronde T, Saggese M, Ramalingam SS. Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress. Clin Lung Cancer. 2021 Jul;22(4):371-375. doi: 10.1016/j.cllc.2020.11.004. Epub 2021 Jan 6.
PubMed 33558193